This page explains Egypt’s system. Its licences, funding rules and prescribing criteria do not determine access in the UK.
Does the diabetes formulary describe every semaglutide use?
No. The Wegovy product assessment addresses weight management separately from the formulary's diabetes-focused semaglutide entry.
Product-specific evidence
The EDA Wegovy assessment concludes approval for the listed FlexTouch presentations and describes weight management in defined adult and adolescent groups. This is stronger evidence than a retail advertisement, but it cannot confirm present stock in a particular pharmacy.
Keep brands and indications distinct
The national endocrine formulary's semaglutide entry describes diabetes treatment and states that biological medicines should be prescribed and dispensed by brand. Discuss the actual locally authorised product with the clinician rather than choosing an ingredient from a price list.
Funding remains a local question
The documents reviewed do not establish a national funded pathway for GLP-1 obesity treatment. Ask your public service or insurer whether the proposed indication is covered and what authorisation or referral is required. No national retail price has been verified here.
The scope for UK readers
Egypt's assessment is country-specific evidence and does not establish a UK medicine licence or pharmacy supply. It helps explain international treatment developments. A personal UK decision still needs current UK guidance, clinical assessment and a GBP quote for appropriate continuing care.
Keep these four questions separate
Access
Egyptian assessment and product-specific requirements
Funding
National obesity-treatment funding pathway not verified
Cost context
No national EGP price or UK price equivalence asserted
Regulatory source
Egyptian Drug Authority
Sources & further reading
Sources checked . These links support the information above; they do not imply endorsement of this website.
Written for a UK audience by the Health Comparisons editorial team. This page is an information resource and has not been presented as a clinician’s personal recommendation. Discuss treatment decisions with your prescriber.
Read our editorial standards →
Compare prices